mfn-cus-2021 | Nanologica

Exercise of Rights in Nanologica’s Stock Option Program

30 June, 2021

In Nanologica's stock option program 2018/21 exercise of rights in Nanologica’s stock option program has increased the number of shares in the company by 371,346 to 28,165,826 shares. As a result, the share capital increases to SEK 11,548,761. At Nanologica's Annual General Meeting on May 31, 2018, it was resolved to establish an incentive program of a maximum of 484,883 stock options for the company's employees. Each option entitles the holder to subscribe for one

Nanologica’s patent granted in Australia

16 June, 2021

The Australian Patent Office has granted Nanologica’s patent titled ”A process for manufacturing porous silica particles loaded with at least one bioactive compound adapted for lung, nasal, sublingual and/or pharyngeal delivery”. The patent protects the company’s technology platform NLAB Spiro® by giving exclusivity on methods for producing particles loaded with active pharmaceutical ingredients for lung delivery, among other dosage forms. ” This patent was granted in Europe last year and it is pleasing that we

Nanologica’s CEO sells shares and buys options

8 June, 2021

CEO Andreas Bhagwani has privately and through his company Vega Bianca AB divested 323,000 shares in Nanologica AB for private economic reasons. At the same time, he exercised 227,566 options to shares. Following the transactions, Andreas Bhagwani's holdings in Nanologica AB amounts to 2,019,764 shares, equivalent to 7.3 percent of the total number of shares in Nanologica, and 165,000 options. "The sale is made for personal economic reasons. Nanologica remains my largest investment and commitment,

About us

Nanologica is a Swedish life science tools company that provides input goods to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.